UC Supplement Shortlist — Berberine, Omega-3, Liposomal Glutathione

Paul asked about three UC supplement ideas from email: berberine, Juice+ Omega / omega blend, and liposomal glutathione. This is a quick evidence-aware triage, not a treatment recommendation.

Short answer

• Most noteworthy: berberine and the glutathione/NAC redox branch are worth tracking in the UC notes.
• Berberine: there is a small human UC phase I trial using berberine 900 mg/day with mesalamine for 3 months. It was mainly a safety/cancer-prevention-risk trial in UC patients with dysplasia, but it reported improved colonic histology signal. It is interesting, but not yet strong remission evidence.
• Liposomal glutathione: direct UC evidence for liposomal glutathione itself looks weak/absent in this quick pass. The more evidence-grounded adjacent idea is N-acetylcysteine (NAC) as a glutathione precursor/redox support; one randomized UC remission-maintenance trial/preprint reported fewer relapses and lower fecal calprotectin/ESR/hs-CRP during steroid taper.
• Omega-3 / fish oil / Juice+ Omega-type blends: biologically plausible and some biomarker/active-disease signals, but systematic reviews are mixed and maintenance-of-remission evidence is not convincing. Treat as general inflammation/nutrition support, not a primary UC remission lever unless a specific dose/formulation and tracking plan is chosen.

Item-by-item notes

Berberine

Evidence signal: low-to-moderate, early human signal.

A phase I randomized double-blind trial in Chinese patients with biopsy-proven UC and grade 2 dysplasia tested berberine 900 mg/day vs placebo for 3 months, on a mesalamine background. Main goal was safety. The abstract reports:

• one possible related grade 3 transaminase elevation and one grade 1 nausea in 12 berberine-treated participants;
• no such toxicities in 4 placebo participants;
• significantly higher plasma berberine after treatment;
• significantly decreased Geboes histology grade in colonic tissue;
• nonsignificant effects on other tissue/blood biomarkers.

Why it matters for Paul: berberine is not just a generic “anti-inflammatory herb” here; there is at least a small human UC tissue-signal trial. It may connect to microbiome, epithelial metabolism, and inflammation branches.

Cautions: berberine has drug-interaction and liver-enzyme considerations; the trial was tiny and not designed as a UC remission induction/maintenance trial. It should be clinician-discussion only, especially if on UC meds, antibiotics, anticoagulants, diabetes/BP meds, or if liver enzymes/ALP are being watched.

Liposomal glutathione / NAC / redox support

Evidence signal: glutathione rationale is mechanistically interesting; direct liposomal-glutathione UC clinical evidence not found in this quick pass; NAC has more direct UC evidence.

The UC redox branch is already in the wiki: impaired butyrate oxidation, increased H₂O₂/ROS, thiolase redox sensitivity, and oxidative-stress questions. Liposomal glutathione fits this hypothesis broadly, but the quick Scite pass did not find a direct UC clinical trial for liposomal glutathione.

A more clinically visible adjacent intervention is N-acetylcysteine (NAC). A double-blind randomized controlled clinical trial/preprint reported that UC patients on steroid taper receiving NAC 400 mg twice daily for 16 weeks had fewer relapses than placebo during 22-week follow-up, with lower fecal calprotectin, ESR, and hs-CRP. This is interesting because NAC supports glutathione/redox biology and is closer to objective UC outcomes than generic glutathione claims.

Why it matters for Paul: this strengthens the “safe oral redox support” research branch more than it proves liposomal glutathione specifically. It also gives a clinician-discussion question: if investigating redox support, is NAC more evidence-grounded than liposomal glutathione for UC?

Cautions: supplement quality, GI tolerance, medication interactions, asthma/bronchospasm history, anticoagulant/bleeding context, and current flare status matter. Do not treat this as a substitute for mesalamine/local therapy/clinician-directed UC care.

Omega-3 / fish oil / Juice+ Omega-type blend

Evidence signal: mixed.

A 2023 systematic review concluded seafood-derived omega-3 may reduce inflammatory/oxidative mediators and may improve some UC clinical/histologic/sigmoidoscopic scores, but also emphasized inconsistent findings and need for better studies. A 2014 IBD fish-oil review described modest potential benefit in active UC but little/no role in remission maintenance. The 2011 systematic review/meta-analysis of omega-3 for maintenance found no UC relapse-rate benefit and noted more diarrhea/upper-GI symptoms in omega-3 groups.

Juice+ Omega-specific note: I could not verify the exact current Juice+ product label in this pass because the manufacturer site blocked automated access. Treat this as an omega blend question until the label/dose/ingredients are checked. Key practical distinction: EPA/DHA dose and source matter; ALA-only or low-dose blends are not equivalent to trial-dose fish oil.

Why it matters for Paul: omega-3 is plausible for systemic inflammation and lipid biology, but it is not currently a top-tier UC lever compared with dairy-trigger tracking, distal/local therapy, constipation/contact-time strategy, sleep, mucus-PC/barrier repair, beneficial commensals, and redox/NAC questions.

Cautions: possible diarrhea/upper-GI effects, reflux, bleeding-risk considerations at higher doses, product oxidation/rancidity, and anticoagulant/NSAID interactions.

Clinician questions created

• For a redox-support branch, is NAC more evidence-grounded than liposomal glutathione for UC, and would it be safe with current medications/labs?
• If considering berberine, should liver enzymes and interactions be reviewed first, especially given Paul’s ALP/liver-axis tracking?
• If considering omega-3, what EPA/DHA dose and formulation would be meaningful, and would diarrhea/reflux/bleeding-risk outweigh likely benefit?
• Which objective marker would define success for any supplement trial: mucus/blood, stool form/evacuation, fecal calprotectin, CRP/ESR, endoscopy/histology, or sleep/stress-adjusted symptom tracking?

Source audit

• Paul email / personal note: raw source saved at raw/personal-notes/2026-06-28-uc-supplement-email-berberine-omega-glutathione.md.
• Xu et al. 2020, A Phase I Trial of Berberine in Chinese with Ulcerative Colitis, DOI 10.1158/1940-6207.CAPR-19-0258.
• Shirazi et al. 2020 preprint, Effect of N-acetylcysteine on remission maintenance in patients with ulcerative colitis, DOI 10.21203/rs.3.rs-37117/v1.
• Mardani-Nafchi & Mohammadi-Nafchi 2023, The effect of seafood oil omega-3 supplementation on ulcerative colitis remission: A systematic review, DOI 10.34172/jsums.2023.761.
• Farrukh 2014, Is there a role for fish oil in inflammatory bowel disease?, DOI 10.12998/wjcc.v2.i7.250.
• Turner et al. 2011, Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses, DOI 10.1002/ibd.21374.

Promotion decisions

• Promoted to Proctitis Methods and Protocols under supplements.
• Promoted to Thiolase Branch in UC as a safe oral redox-support question, distinguishing liposomal glutathione from NAC.